A new malaria vaccine candidate is offering fresh hope in the global fight against one of the world's deadliest infectious diseases.

In a major development, the University of Oxford has signed a licensing agreement with the Serum Institute of India (SII) to accelerate the development and manufacturing of R78C, a next-generation malaria vaccine.

The announcement comes at a time when malaria continues to pose a significant global health burden, particularly in low- and middle-income countries. According to the World Health Organization (WHO), malaria remains a leading cause of illness and death, especially among children in sub-Saharan Africa.

While recent years have seen progress with vaccines like R21/Matrix-M, scientists say newer approaches are needed to improve long-term protection and tackle the parasite more effectively. The R78C candidate represents such an effort, designed to target multiple stages of the malaria parasite's lifecycle.

Experts believe that collaborations like this, combining scientific innovation with large-scale manufacturing capabilities, could be key to making effective vaccines accessible worldwide. Here's what we know about the R78C vaccine and why it matters.

Source:Ndtv